Bioverativ Inc (BIVV) Receives $59.58 Consensus Target Price from Analysts
Shares of Bioverativ Inc (NASDAQ:BIVV) have been assigned an average recommendation of “Hold” from the seventeen ratings firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, ten have given a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $59.54.
BIVV has been the topic of a number of research analyst reports. Jefferies Group LLC reissued a “buy” rating and set a $70.00 price objective (up previously from $67.00) on shares of Bioverativ in a report on Wednesday, August 9th. Cowen and Company reissued a “buy” rating and set a $80.00 price objective on shares of Bioverativ in a report on Friday, August 4th. Deutsche Bank AG initiated coverage on shares of Bioverativ in a report on Friday, June 23rd. They set a “hold” rating and a $65.00 price objective on the stock. Zacks Investment Research raised shares of Bioverativ from a “sell” rating to a “hold” rating in a report on Thursday, August 24th. Finally, Evercore ISI initiated coverage on shares of Bioverativ in a report on Wednesday, August 16th. They set an “in-line” rating and a $58.00 price objective on the stock.
Bioverativ (BIVV) traded down 2.23% on Wednesday, hitting $55.18. 1,537,212 shares of the company traded hands. The stock’s 50-day moving average is $56.37 and its 200 day moving average is $54.74. Bioverativ has a 12 month low of $41.88 and a 12 month high of $57.82. The stock has a market cap of $5.97 billion and a PE ratio of 13.12.
Bioverativ (NASDAQ:BIVV) last released its quarterly earnings data on Wednesday, August 2nd. The biotechnology company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.17. The company had revenue of $289.10 million for the quarter, compared to analysts’ expectations of $269.00 million. The firm’s quarterly revenue was up 37.5% on a year-over-year basis. During the same period in the prior year, the firm posted $0.59 EPS. Equities research analysts expect that Bioverativ will post $2.89 earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Bioverativ Inc (BIVV) Receives $59.58 Consensus Target Price from Analysts” was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.thecerbatgem.com/2017/09/16/bioverativ-inc-bivv-receives-59-58-consensus-target-price-from-analysts.html.
In other Bioverativ news, Director Brian S. Posner purchased 1,000 shares of Bioverativ stock in a transaction on Wednesday, August 9th. The shares were bought at an average price of $59.19 per share, with a total value of $59,190.00. Following the completion of the acquisition, the director now directly owns 6,693 shares of the company’s stock, valued at $396,158.67. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, insider Diantha Duvall sold 818 shares of the company’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of $60.47, for a total transaction of $49,464.46. Following the completion of the sale, the insider now directly owns 2,128 shares in the company, valued at approximately $128,680.16. The disclosure for this sale can be found here.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Stock Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related stocks with our FREE daily email newsletter.